Our look is new. Our purpose is the same. Learn more about our brand evolution.
by Amanda Hill, Denver, Colorado FSHD clinical researchers recently published what may soon become a standard battery of assessments for use in clinical trials, an exciting and essential milestone for […]
The Spring edition of FSH Watch is here! Read on to catch up on all the happenings so far in 2018: This issue‘s highlights include: -Jim Chin elected Chair of […]
The Massachusetts-based biotech, Acceleron Pharma, issued a press release this morning with some encouraging news for FSH muscular dystrophy patients about its experimental drug, ACE-083 (see related story). Here is […]
Muscular dystrophy is a part of me, but it does not have me by DAVID YOUNGER, PhD Austin, Texas I was diagnosed with FSHD when I was about four, at […]
Preliminary results from the ongoing phase 2 clinical trial of ACE-083 in FSHD patients were presented today at the American Academy of Neurology 70th Annual Meeting in Los Angeles, California.The […]
